AMRN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

14.779

Open

14.600

VWAP

14.47

Vol

49.48K

Mkt Cap

301.03M

Low

14.160

Amount

715.95K

EV/EBITDA(TTM)

--

Total Shares

20.80M

EV

1.15M

EV/OCF(TTM)

0.17

P/S(TTM)

1.42

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Show More

Events Timeline

(ET)

2026-03-18

08:40:00

Amarin Celebrates New Guidelines Including CV Risk Treatment for Hypertriglyceridemia Patients

2026-02-25 (ET)

2026-02-25

07:10:00

Amarin CFO Says Q4 Cash Flow Turned Positive Ahead of Schedule

2026-02-25

07:10:00

Amarin Reports Q4 Revenue of $49.2M, Down from $62.3M Last Year

2026-01-09 (ET)

2026-01-09

07:10:00

Amarin Discusses Innovations in Triglyceride Therapies and VASCEPA Outlook

2026-01-08 (ET)

2026-01-08

07:10:00

Amarin Expects 2025 Net Revenue Between $212M and $217M

2026-01-08

07:10:00

Aaron Berg Expects Best Opportunities for VASCEPA/VAZKEPA Business in 2026

2025-11-09 (ET)

2025-11-09

19:08:52

Amarin reveals new post hoc analysis regarding aspirin usage in REDUCE-IT study

News

Fool

Amarin Faces Challenges, Restructures for Survival

NASDAQ.COM

03-07NASDAQ.COM

Amarin Faces Patent Loss and Competitive Pressures

Yahoo Finance

03-07Yahoo Finance

Amarin Faces Competition and Restructuring Challenges

Fool

Amarin's Bleak Prospects vs. Novartis' Strong Investment Appeal

seekingalpha

02-25seekingalpha

Amarin Misses Q4 2025 Revenue Forecasts, Shares Drop

seekingalpha

02-25seekingalpha

Amarin Q4 Earnings: Revenue Decline but Cash Increases

Valuation Metrics

The current forward P/E ratio for Amarin Corporation PLC (AMRN.O) is -686.00, compared to its 5-year average forward P/E of -59.88. For a more detailed relative valuation and DCF analysis to assess Amarin Corporation PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-59.88

Current PE

-686.00

Overvalued PE

127.12

Undervalued PE

-246.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-52.68

Current EV/EBITDA

-0.46

Overvalued EV/EBITDA

129.09

Undervalued EV/EBITDA

-234.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

2.05

Current PS

1.64

Overvalued PS

2.77

Undervalued PS

1.32

Financials

AI Analysis

Annual

Quarterly

Whales Holding AMRN

Kynam Capital Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Amarin Corporation PLC (AMRN) stock price today?

The current price of AMRN is 14.47 USD — it has decreased -0.89

What is Amarin Corporation PLC (AMRN)'s business?

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

What is the price predicton of AMRN Stock?

Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Amarin Corporation PLC (AMRN)'s revenue for the last quarter?

Amarin Corporation PLC revenue for the last quarter amounts to 49.22M USD, decreased -21.00

What is Amarin Corporation PLC (AMRN)'s earnings per share (EPS) for the last quarter?

Amarin Corporation PLC. EPS for the last quarter amounts to -0.06 USD, decreased -97.46

How many employees does Amarin Corporation PLC (AMRN). have?

Amarin Corporation PLC (AMRN) has 80 emplpoyees as of March 25 2026.

What is Amarin Corporation PLC (AMRN) market cap?

Today AMRN has the market capitalization of 301.03M USD.